WASHINGTON — When the 2026-27 flu season opens this September, older Americans will find something genuinely new at the pharmacy: a flu shot built on the same mRNA technology that powered the COVID-19 vaccines, cleared by the Food and Drug Administration on August 5 and measurably more effective than anything previously licensed for seasonal influenza. The problem is that many of them may have to pay for it out of pocket.
The FDA approved mFLUSIVA on August 5, granting Moderna’s mRNA-based influenza vaccine authorization for adults 50 and older, part of a consequential stretch of agency decisions in recent weeks that also included a cancer drug clearance that nearly doubled survival in one of medicine’s hardest-to-treat diagnoses. The agency noted in its approval that the vote from its external vaccine advisory committee was unanimous. mFLUSIVA is the first mRNA flu vaccine licensed anywhere in the world. It also arrived in the middle of a federal legal dispute that has paralyzed the government’s vaccine advisory panel, severing the administrative link that normally triggers mandatory zero-cost coverage under the Affordable Care Act.
The clinical case for mFLUSIVA is straightforward. In a Phase 3 trial enrolling 40,805 adults 50 and older across 11 countries, participants who received the vaccine developed lab-confirmed influenza at a rate of 2.0 percent, compared with 2.8 percent among those given a licensed standard-dose shot, a relative improvement of 26.6 percent. The vaccine outperformed the comparator across all three influenza strains assessed: H1N1, H3N2, and B/Victoria. No new safety signals emerged during the trial.
Side effects were more common than with standard flu shots, following the pattern established by mRNA COVID-19 vaccines. Injection-site pain affected 65.8 percent of participants, fatigue was reported by 45.1 percent, and 37.8 percent experienced headache. Those reactions were mild to moderate and resolved quickly in the vast majority of cases. Most clinicians reviewing the data describe the trade-off as favorable: meaningfully better protection at the cost of a sorer arm for a day or two.
The FDA issued two distinct approvals based on age. Adults 50 to 64 received traditional full approval, where the trial data satisfied the most demanding evidentiary standards. Adults 65 and older received accelerated approval, a conditional clearance permitting broad distribution while Moderna completes a postmarketing confirmatory trial comparing mFLUSIVA against a high-dose influenza vaccine. High-dose and adjuvanted flu shots have been the standard-of-care option for adults 65 and older for years because of established immune response advantages in that age group, as the CDC has long recommended in its flu vaccination guidance for older adults. Whether mFLUSIVA can match or surpass them head-to-head for the 65-plus group remains the central open question.
What the approval does not resolve is whether the vaccine will actually be accessible. Under the ACA, private insurers must cover any vaccine that the Advisory Committee on Immunization Practices formally recommends, at no cost to patients. Medicare Part B similarly relies on ACIP recommendations to determine which vaccines seniors receive at no charge. The system has delivered zero-cost flu shots to insured adults every season for years.
ACIP cannot function right now. A March 2026 preliminary injunction issued by US District Judge Brian Murphy invalidated all committee votes made after June 11, 2025, while federal courts review legal challenges to how the committee was reconstituted. The First Circuit Court of Appeals has received an emergency stay request from the Department of Health and Human Services but has not acted on it. Until those proceedings conclude, mFLUSIVA cannot receive an ACIP recommendation, and without that recommendation, insurers face no legal requirement to cover it at no cost to patients, Fox News noted in its coverage. AHIP, the health insurance trade association, publicly committed to covering vaccines recommended before September 1, 2025, without cost-sharing through the end of 2026. mFLUSIVA, approved two months after that cutoff, is not included.
The practical result is direct: patients who request mFLUSIVA this fall may face an out-of-pocket charge. Moderna has not announced a retail price, but mRNA products have consistently commanded a premium over standard formulations. For Medicare beneficiaries and ACA marketplace enrollees who rely on cost-sharing protections, the coverage gap is the default outcome until a court acts.
The broader stakes are technological. mRNA flu vaccines have been an aspiration in influenza research for decades because the existing egg-based and cell-culture manufacturing platform constrains how quickly producers can respond to strain changes. mRNA vaccines can in principle be redesigned and produced faster, with the possibility of updating formulations if circulating strains diverge from predictions. mFLUSIVA does not yet deploy that flexibility; it is locked to strain selections made months in advance like its predecessors. But its regulatory clearance opens the door. Moderna has indicated that the mFLUSIVA approval unblocks its combination vaccine program, which aims to pair influenza protection with COVID-19 and RSV coverage in a single injection.
The shingles vaccine Shingrix offers the relevant precedent: rapid, broad uptake among adults 50 and older once ACIP recommended it and insurers were required to cover it at no cost. mFLUSIVA represents a comparable advance in influenza protection for the same age group. What it lacks, entering its first season, is the coverage infrastructure that made Shingrix adoption so swift and widespread.
Moderna expects mFLUSIVA to reach select pharmacies in the coming weeks. The First Circuit has given no indication of when it will act on the stay request. For older adults who want the better vaccine and can absorb the cost, the option is within reach. For those who cannot pay out of pocket, access is effectively deferred, pending a federal court’s timeline that nobody involved in the litigation is predicting.
